Traditional antibody dependent cellular cytotoxicity (ADCC) assays use donor derived natural killer (NK) or peripheral blood mononuclear cells, but donor genetic variability and the technically challenging nature of the assay means that alternative in vitro assay formats are required. We explored the utility of two reporter gene cell lines, the J2 and J9, as surrogate effector cells for ADCC assays. Both express the ADCC relevant Fc␥ receptor CD16, crosslinking of which leads to firefly luciferase expression. For anti-CD20 rituximab and anti-HER2 trastuzumab (both IgG1 monoclonal antibodies, mAbs) a dose dependent firefly luciferase response was observed exclusively in the presence of their respective targets, representing the molecular interaction which potentiates ADCC activity. Importantly, both surrogate effector and NK cell based assays gave statistically similar values for rituximab ADCC activity. Increased engagement with target cell bound mAbs was determined to be cytotoxic for the J2 and J9 cell lines at the assay end point (at which luciferase expression is measured). However, use of the J9 cells containing the constitutively expressed renilla luciferase gene enabled data normalisation and corrected for fluctuations in both cell number and viability providing an advantage over currently available surrogate effector cell-lines. Abrogated ADCC activity with IgG4 mAbs, but enhanced activity with an IgG1 non-fucosylated mAb, was seen with the J9 cell line, as expected. Additionally, two rituximab products (biosimilars in development) with similar binding by flow cytometry, N-glycan profiles using HPLC and CD16 binding by surface plasmon resonance showed comparable ADCC activity to Mabthera. The ADCC activity of another anti-CD20 mAb, ofatumumab, reported only with primary cell based assays to date was also measured. This is the first report of a dual reporter gene based ADCC assay.
Introduction
The therapeutic use of monoclonal antibodies (mAbs) is now well established. Most of the ∼50 approved mAb products are used in the treatment of malignant and autoimmune diseases [1] . Biosimilar mAbs, which must demonstrate high similarity to the innovator product on which they are based, and novel and more complex antibody variants, have recently also gained approval. The therapeutic value of mAbs derives from their various mechanisms of action including preventing receptor overstimulation, ligand neutralisation, direct apoptosis, complement dependent Currently, most therapeutic mAbs are of IgG1 subclass, although several IgG2 and IgG4 antibodies have also been developed, the latter being used when effector cell activity is not required [7] . Since the mammalian cell expression systems that are employed for production of most mAbs are sensitive to environmental factors, post-translational modifications are carefully monitored, as these can have important implications for both the efficacy and safety of the final product [8] . This extends to the composition of the N linked glycans present on a mAb which confers structural stability, but also influences ADCC activity [9] . For example, whilst deglycosylation completely inhibits ADCC, defucosylation results in increased binding affinity to CD16a which mediates greater ADCC activity [10] .
Traditionally, target cell death due to ADCC activity has been studied in vitro using peripheral blood mononuclear cells (PBMCs), or semi-purified NK cells. Such assays can be challenging, with complications arising not least from inter-donor variability of cells [11] . Both the immune status and genetic background of a donor, including possession of the 158 V or 158F CD16a alleles, and copy number variation at the CD16 gene locus, can give rise to significant variability in ADCC activity [12] . Difficulties with ADCC assays can also result from the readouts used. Chromium 51 ( 51 Cr) release has conventionally been used as a marker for target cell death, yielding highly sensitive results with low background signal [13] . In order to eliminate concerns associated with radioactivity, other markers have been evaluated, for example, calcein-acetoxymethyl, a fluorescent dye which is well retained by pre-loaded target cells. However, in comparison with the 51 Cr assay, spontaneous release of the marker is still high, reaching up to 40% over the course of the assay [14] . Additionally, culture media contains compounds that can auto-fluoresce, which also contributes to non-specific noise [15] . The release of intracellular enzymes lactate dehydrogenase (LDH), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are also often used as markers of cell death. However, it must be appreciated that LDH is not released exclusively by target cells, but also by effector cells, resulting in difficulties with interpretation.
Increasingly, the limitations of using donor derived effector cells are being overcome by the use of transfected NK or T cell lines. The NK92 cell line, for example, has been transfected to enable stable expression of the high or low affinity CD16a receptor [16] . ADCC activity has also been measured as a function of expression of a luciferase reporter gene upon CD16 receptor engagement. Parekh et al. [17] described the application of an engineered CD16-expressing Jurkat T cell line, in which luciferase gene expression is controlled by the nuclear factor of activated T cells (NFAT) transcription factor. For both NK and T cells, a CD16-induced increase in intracellular calcium that results from cross linking by antibodies allows translocation of NFAT to the nucleus, where it can bind to the promoter regions of ADCC relevant genes [18] . Recently, based on their previous work with a transfected human cell line, containing an NFB firefly luciferase reporter gene construct and renilla luciferase gene, Lallemand et al. [19] produced two similarly engineered Jurkat T cell lines, the J2 and J9 lines for use as effectors for ADCC function. Both cell lines express CD16 and contain the NFAT controlled luciferase reporter gene. Luciferase transcription occurs under the control of the chimeric promoter NFAT Activator Protein 1 (AP-1), the latter of which is a heterodimer of Fos and Jun proteins activated by protein kinase C. Like NFAT, AP-1 is also regulated by downstream signals [20] . In order to account for any fluctuation in cell number, the J9 cell line contains an additional renilla reporter gene expressed by SV40, a promoter of constitutively expressed T cell genes.
In this paper, the utility of the J2 and J9 cell lines as surrogate effector cells for measuring ADCC activity of mAbs is demonstrated. Initial optimisation and characterisation of the assay were carried out using the well-established ADCC-mediating mAb rituximab, which targets B cell lymphocyte antigen CD20 and is widely used in combination with chemotherapy for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and also treatment of rheumatoid arthritis [21] . Trastuzumab, which targets human epidermal growth factor receptor 2 (HER2) over-expressed in ∼ 25% of breast and some stomach cancers, and cetuximab against epidermal growth factor receptor (EGFR), efficacious in colon, head, neck and lung cancers, were then used to demonstrate ADCC efficacy with adherent cell lines [22, 23] . The value of J9 cells, which constitutively express the renilla luciferase reporter gene, in normalising the data is examined: this is a feature which is currently not present in other available reporter gene cell lines used to determine ADCC. Having confirmed the assay's sensitivity to glycosylation-both the presence of the Nglycan and fucosylation-the J9-based assay was used to compare the ADCC activity of two rituximab biosimilar products in development in conjunction with other analytical techniques. Finally, the fully human anti-CD20 antibody ofatumumab was examined, revealing that the J9 ADCC assay results corroborate with a limited report of its increased ADCC activity compared to rituximab.
Materials and methods

Reagents
Anti-HER2 trastuzumab (Herceptin), anti-CD20 antibodies rituximab (Mabthera), (both from Roche, Basel, Switzerland) and ofatumumab (Arzerra; Novartis, Basel, Switzerland), and anti-EGFR cetuximab (Erbitux; Merck, Darmstadt, Germany) and panitumumab (Vectibix; Amgen, CA, USA) are therapeutic products. The IgG1 and IgG4 rituximab and trastuzumab isotypes, nonglycosylated and non-fucosylated rituximab were from InvivoGen (CA, USA). Other reagents used were dead cell apoptosis kit containing annexin V and propidium iodide (Fisher Scientific, Loughborough, UK), anti-Human IgG (Fc gamma-specific) PE, antiHuman CD28 APC and Brilliant Violet 421 anti-Human CD56 (NCAM) (Affymetrix UK Ltd, High Wycombe, UK); anti-human CD16 (Cambridge Bioscience, Cambridge, UK); anti-human CD19 PE (BioLegend, CA, USA). IgG from human serum, used as a standard for HPLC N-glycan analysis, was obtained from Sigma Aldrich (MO, USA).
Cell culture
Human B cell lines: WIL2-S (lymphoblastoid cell line), Raji (derived from a Burkitt's lymphoma patient) and Daudi (lymphoblastoid) cells were cultured in complete medium: RPMI (Roswell Park Memorial Institute) 1640 (Sigma-Aldrich) containing 10% Foetal calf serum (FCS, Labtech, South American origin), penicillin/streptomycin (1.25 mg/ml), 1% glutamine supplemented (both from Sigma Aldrich). For Daudi cells, the medium was supplemented with 1 mM sodium pyruvate (Sigma Aldrich). SKBR3 cells from ATCC (Middlesex, UK) were cultured in McCoy's 5A medium (Sigma Aldrich) and A431 cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium, Sigma Aldrich) both with 10% FCS; penicillin streptomycin (1.25 mg/ml) 1% glutamine supplemented. The transfected J2 and J9 (ENS Cachan, Villejuif, France) were cultured in RPMI complete medium with 150 g/ml Hygromycin and 50g/ml Zeocin, and specifically 12.5 mM Puromycin for J9 cells (all from InvivoGen). PBMC's were separated from blood (obtained from leukocyte cones (NHSBT, Colindale)) using Histopaque-10771 (Sigma Aldrich). Following negative selection of NK cells with human NK cell Isolation Kit (Miltenyi Biotec, Bergisch Galdbach, Germany), NK cells were cultured in NK cell culture media (55% DMEM; 1% sodium pyruvate (Sigma Aldrich)); 30% F-12 nutrient mixture, 1% non-essential Amino Acids, and 50 M mercaptoethanol (all Gibco, Paisley, UK); 1% penicillin/streptomycin with IL-2 at 200 IU/ml.
Antibody dependent cellular cytotoxicity (ADCC)
2.3.1. Reporter gene based assay 24 h prior to the assay, the density of J2 or J9 effector cells was set at 5 × 10 6 cells/ml, and suspension target cells at 4 × 10 6 cells/ml. For the assay, 10 4 target cells were washed and resuspended in complete medium with serial dilutions of antibody (doubling dilutions, starting at 500 ng/ml) for 30 min at 37 • C in a 96 well cell culture plate (Sigma-Aldrich). 8 × 10 4 of surrogate effector cells in complete medium were then added and incubated at 37 • C for 18 h, after which Steadylite plus TM (PerkinElmer, Beaconsfield,UK) for the J2 cell based assay, or Dual-Glo (Promega, WI, USA) for the J9, were added according to manufacturer's instructions in order to enable luminescence detection. Plates were read using a MicroBeta2 Plate counter (PerkinElmer). Stop & Glo (Promega) reagent was added to the J9 based assay to enable Renilla luciferase detection and the plates read again. Prior to analysis with GraphPad Prism 5, the luciferase response was normalised by dividing the firefly luciferase signal with that of Renilla luciferase.
NK cell based assay
The assay was performed in NK cell culture media without IL-2. Daudi cells were loaded with 5 M calcein AM (ThermoFisher Scientific, UK) in RPMI for 20 min at 37 • C.Dilutions of rituximab (starting at 5 g/ml) were added in equal volume to washed Daudi cells at a final density of 2 × 10 6 cells/ml in round bottomed 96 well clear plates for 30 min at 37 • C. Washed NK cells at a density of 2 × 10 5 cells/ml were added in a 2:1 vol ratio to the target cells. This was incubated for 4 h at 37 • C after which the plate was centrifuged at 250g for 3 min. 50 l of supernatant per well was transferred to a white 96-well flat bottomed plate and fluorescence read at 490/520 nm. Target cell% cytotoxicity was calculated using the following equation:
(Experimental value-spontaneous target cell release control)/(Target cell maximum release control-spontaneous target cell release control) × 100
For determining ADCC activity, EC50 values were determined using the four parameter model to fit sigmoidal curves with GraphPad Prism 5 and CombiStats, the latter specifically for assay variation and evaluation of rituximab biosimilars in development.
Complement dependent cytotoxicity
WIL2-S cells at 1 × 10 6 /ml were loaded with calcein AM as described. Cells were washed twice and resuspended to 4 × 10 5 cells per ml. An equal volume of cells were incubated with a dilution series of antibody (50 l, starting at 500 or 600 ng/ml) in round bottomed 96 well clear plates for 30 min at 37 • C. After addition of human complement Sera (Sigma Aldrich) or Low-Tox-M Rabbit Complement (Cedarlane, Burlington, Canada), the plate was incubated at 37 • C for 2 h. 20 min prior to the end of this period, 10 l Lysis buffer (ThermoFisher) was added to the "target cell maximum control" and the plate put back. After 2 h, the plate was processed, and target cell% cytotoxicity calculated as described for the NK based ADCC assay.
Flow cytometry
CD20 cell surface expression
To detect the level of CD20 binding to the surface of Raji, WIL2-S and Daudi B cell lines, 1 × 10 5 cells were incubated with 250 ng/ml IgG1 anti CD20 mAb, or IgG1 isotype control anti HER2 mAb for 20 min at room temperature (RT). Binding was detected by incubation with a human IgG, Fc gamma-specific PE conjugate and fluorescence measured at 496 nm using a BD FACS Canto II. Data were analysed, including PE mean fluorescence intensity (MFI) calculated as an indication of CD20 expression, using FlowJo software (FlowJo, Oregon, USA). For assessing the binding of different anti-CD20 mAbs, 1 × 10 5 Raji cells were incubated with different concentrations of anti CD20 antibodies (0, 5, 50, 250 and 500 ng/ml) in FACS flow (0.5% Bovine serum albumin, 0.1% NaN3) at 4 • C for 30 min. Cells were washed, and human IgG Fc specific PE mAb conjugate was then added prior to flow cytometry analysis as described.
Detection of apoptotic cell populations
The experiments were set up using both target and effector cell lines as per the ADCC protocol. After 18 h, cells were washed, resuspended in annexin-binding buffer, and test samples incubated with Alexa Fluor ® 488 annexin V, Propidium iodide (PI) and anti-human CD28 Allophycocyanin (APC) for 15mins at RT in the dark. Fluorescence was measured by excitation at 495 nm, 482 nm and 652 nm for annexin V, PI, and CD28 respectively using a BD FACSCanto II which also calculated compensation. Data were analysed using FlowJo software (FlowJo).
HPLC glycan analysis
Antibodies were desalted with ultrapure water using a 20 kDa micro centrifuge tube filter (Sigma-Aldrich), and recovered in 100 l. N-glycans were released using the PNGase F kit (New England Biolabs, Hitchin, UK) as per manufacturer's procedure and analysed as described previously [24] . Briefly, samples were denatured with denaturing buffer (10%) for 15 min at 37 • C after which enzyme buffer (10%), PNGase F (2000 units) and NP40 (10%) were added and incubated at 37 • C for 16-20 h. The reaction was stopped and denatured protein was precipitated with 1 M HOAc. This mixture was passed through a C18 polymeric cartridge (Strata-X; Denver, CO, USA) to remove most soluble peptides, and purified again using HPLC on a TSK-Gel Amide80 column (5 m, 250 × 4.6 mm). Released N-glycans were determined based on hexose (galactose) content according to Thobhani et al. [25] and labelled with fluorophore 4-Aminobenzoic acid (4ABA). Labelled N-glycans were resolved according to size on an Amide 3.5 m column (6 × 250 nm, XBridge; London, UK), detected by fluorescence excitation at 296 nm and emission at 359 nm.
Fab fragment generation
Rituximab Fab fragments were generated using a Fab Micro preparation kit (ThermoFisher) according to manufacturer's instructions, and identity confirmed using SDS PAGE.
Surface plasmon resonance
Experiments were performed using a Biacore T100 system (GE Healthcare, Uppsala, Sweden). Analysis temperature was set to 25 • C and sample compartment temperature set to 15 • C. Recombinant human CD16a extracellular domains (176 Val, C-terminal His Tag), equivalent to Fc␥R IIIA 158F/V were purchased from Sino Biological, Inc (PA, USA). Fc␥Rs were reconstituted in running buffer (HEPES Buffered Saline-N; GE Healthcare, Amersham, UK), aliquoted, stored at −70 • C, and thawed only once. An NTA Sensor chip was used with the NTA reagent kit (GE) according to manufacturer's instructions. The chip surface was first conditioned with regeneration solution (350 mM ethylenediaminetetraacetic acid (EDTA)) for 60 s at a flow rate of 30 l/min and then saturated with a nickel solution (0.5 mM Nickel) for 2 min at 10 l/min. The CD16a His tagged ligand at 600 ng/ml in running buffer (without EDTA) and captured onto the surface of the chip by injecting for 2 min at 10 l/min. 5 injections of antibody (25-2025 nM) were repeatedly injected for 160 s at 10 l/min, with a dissociation time of 300 s. This cycle was repeated with the same chip for successive antibodies. Fitting of data was performed with Biacore T100 evaluation software using two step kinetic analyses.
Results
Optimisation of target and effector cells
In order to function as surrogate effector cells for ADCC activity, the specificity of the luciferase response from both J2 and J9 CD16 expressing surrogate cell lines was investigated. Only engagement of target antigen on Raji B cells by anti CD20 mAb rituximab (RTX) enabled firefly gene expression from both cell lines (Fig. 1A and C). Renilla luciferase, expressed by the J9 cell line, was used to determine the normalised dose response (a ratio of firefly luciferase relative fluorescence intensity (RFI): renilla luciferase RFI) which also reflected this specificity (Fig. 1B) . The absence of any firefly expression when using anti Her-2 trastuzumab (Her)-a non-CD20 specific IgG1 mAb control, with Raji target cells confirmed that specific target antigen interaction is required to crosslink CD16 and induce luciferase expression. Additionally, neither RTX nor Her in the absence of target cells, or the presence of Raji target cells alone, had any effect.
As with traditional ADCC assays, the J2 and J9 surrogate effector cell line-based assays were optimised with respect to several key parameters. Several different target to effector ratios were tested which produced similar dose response curves, and a ratio of 1:8 was selected (Supplementary Fig. 1 ). Cell culture conditions prior to use in assay and cell densities for both targets and surrogates for assay were also examined, as well as comparison of a 6 h vs 18 h incubation time after surrogate cell addition, where 18 h was necessary to achieve a full dose response. Lastly, selection of the most suitable target cell line to use with RTX was carried out using three CD20-expressing B cell lines (Raji, WIL2-S and Daudi). metric analysis revealed that WIL2-S cells had the greatest CD20 expression, determined using a secondary antibody against RTX opsonised cells; both Raji and Daudi cells had similar CD20 levels (data not shown). Dose response curves were generated with J2 cells and showed that activity with WIL2-S, Raji and Daudi target cells, as indicated by the maximum RFI-minimum RFI (max-min RFI), decreased respectively (Fig. 1 D) . With the J9 cell line however, (Fig. 1E ), the Raji cell line generated the greatest response before and after normalisation. In order to maintain consistency when testing different anti CD20 antibodies in both assays, the Raji cell line was selected as the target for further studies.
The specific ADCC activity of RTX was also demonstrated using NK cells and Daudi target cells in a conventional ADCC assay (Fig. 2) . A higher dose of RTX (5 g/ml) was required in order to generate a full dose response curve, compared to the J2 and J9 cell based assay (500 ng/ml). Background cytotoxicity of target cells with NK cells alone, or non-specific IgG1 control Her with Daudi cells, varied from donor to donor, ranging from 10 to 50%. The EC50 values (dose at which 50% ADCC activity is mediated) of RTX, measured using both J2 and J9 surrogate cell lines and NK cells, were compared using an unpaired t-test, and determined not to be significantly different (p = 0.05; n = 3).
Advantage of second renilla reporter gene
The advantage and utility of the constitutively expressed renilla luciferase reporter gene-a feature of the J9 cell line-is that it permits correction for fluctuation in cell numbers that may occur due to technical errors or changes in cell viability. Unlike the J2 cell line, the final dose response measurements from J9 cells are expressed as a ratio of firefly luciferase RFI to Renilla luciferase RFI. In order to assess the sensitivity of Renilla expression, increasing densities of J9 cells were incubated with Raji target cells in the presence of RTX or non-specific IgG1 mAb, Her. As expected, in both cases, an increase in Renilla expression correlated with J9 cell density; target cell engagement however appeared to inhibit the response (Fig. 3A) . Additionally, whilst fluctuation across the dose response is expected, Renilla expression appeared to decrease, specifically with Raji target cells and increasing concentrations of RTX (Fig. 3B) . This effect was not a feature of RTX alone as it was also evident with trastuzumab (Her) using the HER2 expressing SKBR3 cell-line as target cells. Considering that this may be an apoptotic effect evident at high concentrations of the target cell specific mAb, both J9 and J2 surrogate effector cell viabilities (at passage 15) were examined with these two mAbs and their respective target cell lines. Propidium iodide (PI) and annexin V were used to analyse CD28 positive J2 and J9 cells by flow cytometry in control conditions and with an upper (500 ng/ml) and lower (1 ng/ml) concentration of RTX with Raji cells or with Her and SKBR3 cells. Whilst the early apoptotic population (annexin V positive) of both cell lines was below 10% with target cells or mAb alone and at 1 ng/ml with target specific cells, a notable change in this population was observed at 500 ng/ml for both target specific antibodies and their target cells (Fig. 3C and  D) . Specifically, there were ∼15% and ∼30% more early apoptotic J2 and J9 cells at 500 ng/ml Her and Mabthera respectively. The late apoptotic population for all samples remained constant (below 10%, data not shown). This effect was further confirmed using J2 and J9 cells at passage 30 with a higher concentration of RTX (1.5 ng/ml and 1.5ug/ml), required in order to reach a plateau, and a ∼20% increase in the early apoptotic population seen. Additionally at this higher passage number, a 10% and 20% increase in the late apoptotic population (annexin V and PI positive) of J2 cells and J9 cells was observed respectively (data not shown). Therefore, normalisation of the dose response, enabled by the renilla luciferase gene in the J9 cell line, is required to compensate for the loss in surrogate effector cell viability which occurs specifically in the presence of target cells and higher concentrations of target specific mAb. Changes in cell physiology, occurring with increasing passage number, may affect bioassay performance. In order to examine whether long term cell culture of the J9 cell line has any impact on the assay, the dose responses of rituximab with J9 cells from several passages (P + 12, P + 17, P + 23 and P + 33) were compared. A notable reduction according to the max-min RFI of each dose response was observed with increasing passage number (Fig. 4A) . Flow cytometric analysis of J9 passages 11, 24 and 33 stained with anti CD16 showed a slight decrease in expression (median fluorescence intensity values were 930, 900 and 850 respectively, average of three separate experiments). This change was not significant (P = 0.18) and therefore the observed decrease in sensitivity of the dose response was not due to a loss of CD16 expression.
J9 ADCC assay variability
For the J9 assay, intra assay variation between replicate samples, and inter-assay variation using similar passage numbers on different days was examined. EC50 values were determined from rituximab dose response curves; n = 3 per assay, 3 independent assays, a total of 9 estimates. Geometric coefficient of variation (GCV) values revealed intra-assay variation to be 6.7%, and interassay variation to be 6.4%. From these values, the overall variation for the assay was 9.9%. Intra assay variation was also determined with Herceptin, which gave a GCV of 6%, n = 9. Further analysis using multiple plates on different days revealed that there was no observable variation between different days, but that the GCV for plate to plate variation was 8% (n = 9).
Compatibility with adherent target cells and dependence on fc region for luciferase expression
Since a number of ADCC mediating mAbs target adherent cells, the utility of the J9 based ADCC assay was examined in this respect. IgG1 cetuximab (anti EGFR) was tested with the EGFR expressing adherent target cell line A431 (Fig. 4B) . As expected, the generation of a specific dose response with cetuximab (CET) and A431 cells, but not target cells alone or RTX (used as a non-specific antigen control) demonstrated that the J9 cell line is compatible with adherent target cells. IgG2 panitumumab (anti-EGFR) was also tested and did not produce a dose response (not shown). This was further confirmed by the dose response observed with Herceptin (Her) and HER2 expressing SKBR3 adherent target cells (Fig. 4C) . Interestingly, with adherent cell lines, it was consistently observed that the normalised signal is lower than that seen with suspension cells.
Structural differences in the IgG subclasses have been shown to result in altered ADCC activity with primary cells. Using the J9 cell line, substituting IgG1 parental RTX and Her with their IgG4 subclass variants produced no luciferase expression by the J9 cell line (Fig. 4C and D) , consistent with its inefficiency in supporting ADCC. Furthermore, a K D value for the IgG4 form could not be derived from SPR analysis, indicating that it does not bind to human CD16 (F/V).
Target cell cytotoxicity by NK cells is contingent upon engagement of the Fc via its Fc receptors. Thus the dependence of Fc binding to CD16 on J9 cells for firefly luciferase expression was assessed by generating a Fab fragment of RTX. Flow cytometric analysis confirmed that the fragment retained its ability to bind CD20 positive Raji cells (data not shown). As expected, in the J9 based ADCC assay using Raji cells, binding of target cells by the Fab fragment did not produce a dose response. This reinforces the fact that luciferase expression by J9 cells is mediated through the Fc region (Fig. 4E) .
The J9 cell line can detect differences in glycosylation on mAbs
It is well established that the presence and composition of the Nglycan on a mAb can dramatically impact ADCC activity. Both nonfucosylated and non-glycosylated forms of RTX (InvivoGen) were used to determine whether the J9 cell line can reflect the reported changes in ADCC activity seen previously [26] .
HPLC analysis of N-glycans released from RTX and nonfucosylated RTX by digestion with PNGase F revealed differences in their glycosylation patterns. Using polyclonal IgG as a standard to identify the different N-glycan species that may be present on a mAb, the absence of fucosylated glycan species G0F, G1F and G2F on the non-fucosylated RTX form was confirmed (Fig. 5A) . Flow cytometry also confirmed that the opsonisation of the modified forms of antibodies to CD20 on Raji target cells was comparable to the unmodified RTX (P = 0.97). When assessed in the J9 assay, as expected, no activity was observed with the non-glycosylated form of RTX, while the non fucosylated form produced an increased response compared to unmodified RTX (Fig. 5B ). This correlated with SPR analyses of these constructs which revealed a higher affinity of non-fucosylated RTX for CD16 (K D = 1 × 10 −9 nM) than RTX (K D = 2.1 × 10 −6 nM). These results suggested that the observed change in activity can be attributed to the Fc association with CD16 and that the J9 cell line can reflect changes in the biological ADCC activity of mAbs with respect to glycosylation.
Assessment of ADCC activity of anti CD20 products
The J9 cell line was also used to measure the ADCC activity of two other RTX products (biosimilars in development): mAb 1 and 2, and another anti CD20 IgG1 mAb, ofatumumab, which targets a different epitope on CD20 to rituximab. Initially, their binding via the Fab and Fc region to CD20 and CD16 respectively were assessed and compared with Mabthera. No significant difference in CD20 binding of Raji target cells of each mAb to Mabthera could be determined from the MFI values obtained via flow cytometry. From four repeat experiments, the average MFI for Mabthera was: 1120; for mAb1: Table 1 CD16 binding affinity of anti CD20 antibodies. SPR was performed using Biacore. 5 injections of mAbs (25-2025 nM) were loaded in increasing concentration across bound CD16 as detailed in "Materials and Methods". KD values from 3 separate experiments on one batch of each mAb were obtained using two state reaction analysis of experimental data with Biacore (T100) evaluation software. 840 (where P = 0.18) and mAb2: 1110 (P = 0.92). CD16 binding was also analysed using SPR analysis (Table 1) . No significant difference were found between the K D values from 3 independent experiments for mAb 1 compared to Mabthera (P = 0.46). The mean K D value for mAb 2 was higher than Mabthera, and determined to be different (P = 0.0095), but it should be noted this is within the same order of magnitude. PNGase F released N-glycan species as analysed by HPLC were similar or indistinguishable for all three mAbs (Fig. 6C) . The dose responses generated with these antibodies using the J9 cell line were comparable to those obtained with Mabthera (Fig. 6A) . For this, a ratio of their EC50 values (mAb/Mabthera) was calculated as a measure of ADCC activity, where 1 indicates identical activity. The geometric mean ADCC activity of mAb 1 was 0.75; upper and lower 95% confidence limits (UCL, LCL) were 0.82 and 0.7 respectively (4 independent experiments). For mAb 2, the geometric mean was 1.14 (UCL: 1.27, LC: 1.03) from 3 independent experiments. Thus, taken together, the J9 assay can be used as an effective tool to compare the ADCC activity of biosimilar antibodies in development. Differences in the N-linked glycan composition can also have an impact upon binding of the complement protein C1q. The complement dependent-cytotoxicity (CDC) activity of each mAb was therefore used as another biological method for detecting any differences. Using CD20 expressing WIL2-S target cells, similar dose responses were generated with both mAbs compared to Mabthera (Fig. 6B) . This was reflected by their EC50 values: 12 ng/ml; 10 ng/ml and 13 ng/ml for Mabthera, mAb1 and mAb2 respectively.
Ofatumumab showed comparable binding to CD20 positive cells as Mabthera, determined by flow cytometry (not shown), and was also assessed using the J9 assay. Despite its similar binding affinity for CD16, as determined by SPR analysis (Table 1) , ofatumumab induced greater ADCC activity in the J9 based assay, and gave a lower EC50 value of 1.7 ng/ml as compared with 15 ng/ml seen with Mabthera (Fig. 7A) . The increased ADCC activity of ofatumumab was also reflected by the NK cell based assay (Fig. 7B) . CDC activity was also slightly higher than RTX, as assessed with WIL2-S cells and human complement (data not shown).
Discussion
Performing ADCC assays using donor derived NK or PBMCs presents several difficulties. Genetic variability across donors, as well as the technically challenging nature of the assay, which includes selecting a reliable readout for target cell death, has resulted in several groups developing alternative ADCC assay formats [27] . Moreover, the need for a reliable means of measuring ADCC has become more pertinent in recent years due to the emergence of biosimilar mAb development [28] . Biosimilar mAb approval must be accompanied by a comprehensive demonstration that they are highly comparable to the originator products upon which they are based [29] [30] [31] . Subtle differences, which are likely to occur during the manufacture of biological therapeutics, can manifest as a difference in biological activity which can lead to meaningful differences in clinical efficacy and safety.
The overall mechanism of action by which Fc receptor ligation may lead to target cell death by immune effector cells is intricate, and regulated by multiple extracellular and intracellular factors [32] . This work demonstrates the reliability and utility of the J9 reporter gene cell line based assay, which measures the potential ADCC activity of a mAb via the CD16 receptor, eliminating the need for PBMC or NK cells in some instances (e.g. batch release purposes). Here, both surrogate effector cell and NK cell-based ADCC assays produced dose response curves for RTX, from which similar ADCC activity (according to their EC50 values) was measured. Whilst target cell death is not measured by the surrogate cell-line based assay, the dose-dependent expression of luciferase upon engagement of CD16 present on both J2 and J9 cells, only with target bound mAb, confirmed that the response reflects the molecular interaction which potentiates ADCC activity. Several key parameters were investigated in order to optimise this assay for use with anti CD20 mAbs, including selection of the CD20 expressing Raji cell line which produced the highest response with the J9 cell line. Although, the respective dose response curves for each B cell line generated by the J2 cell line correlates respectively with their densities of CD20 antigen expression, other factors must be considered. For example, the conformation of CD20 at the surface of each cell line may be different. Further studies could determine whether affinity, and/or avidity of antigen binding by RTX differ between the three cell lines. As increased CD20 expression has been more frequently associated with increased CDC activity [33] , this does not reflect upon the ability of the J9 cell line to measure the potential ADCC activity of a mAb. Tada et al. [34] have published the construction and properties of a Fc␥RIIa (CD32a)-expressing reporter gene cell line to assess the ADCC activity of mAbs in relation to this Fc receptor. This supports the shift towards cell reporter gene based ADCC assays.
Unlike other published data using available reporter gene cell lines to measure ADCC [17, 35] , this work highlights the value of incorporating an additional, constitutively expressed, Renilla luciferase gene in the effector cell line. Although experimental factors can alter constitutive Renilla luciferase expression, potentially invalidating its function as a normalising gene [36] , this does not apply to our observation. Here, a cytotoxic effect of increased engagement with target cell bound mAbs was identified at the assay end point (18 h after addition of J9 cells when luciferase expression is measured) by flow cytometry using annexin V and propidium iodide for both cell lines. This cell death correlated with reduced Renilla expression by the J9 cell line. Supplementary to these results, luciferase expression was examined after a four hour incubation period of J9 cells with target bound mAb. Whereas an upper plateau for the dose response had not been established yet, unlike at 18 h, Renilla expression did not decrease in ADCC mediating conditions-in the presence of both mAb and target cell. For the J9 cell line therefore, Renilla normalisation after 18 h is necessary to correct for the decreased cell viability; if not, this may impact upon the accuracy of the firefly luciferase dose response. This normalising feature is important when considering the necessity of detecting subtle differences in the ADCC activity of biosimilar mAbs.
The dose response curve RFI values with adherent cell lines were significantly lower than with suspension cell lines. This was observed consistently and, from the raw data, is due to the decreased ratio of firefly to Renilla expression. J9 cell CD16 engagement with mAb bound target cells may only occur with cells at the surface of the adherent cell layer that potentially forms prior to J9 addition. Also, since the 3D space of the well has been limited to a layer, the J9 cells may have fewer spatial conformations which enable them to engage with the available mAb bound antigens. However, since these cells must adhere in order to survive long term, seeding the target cells in wells prior to the experiment may increase their viability, and thus improve the signal intensity with J9 cells.
The sensitivity of the NK cell based ADCC assay is heavily dependent on donor genotype, in particular the donor's CD16 polymorphism. Frequently the ex vivo response, or range of target cell% cytotoxicity, is modest. Furthermore, non ADCC specific target cell cytotoxicity can be high. Thus, whilst the dose response signal showed diminution with increasing passage number, possibly due to changes in cell physiology which may affect luciferase reporter gene expression over time rather than CD16 surface expression, creating a bank of cryopreserved cells at a particular passage ensures a continual source of consistently reliable effectors. The format of 'thaw and ready' cryopreserved cells is now routinely used, has been adopted by other groups and helps to reduce the observed inter assay-variability [19, 35] . In our studies, a particular batch of Mabthera was included on each plate alongside each rituximab biosimilar in development as a consistent reference standard for ADCC activity. This enables measurement of relative potency of each sample vs a standard reference, reducing inter-assay variability. The ADCC activity determined using EC50 values of the test samples was then expressed as a ratio (mAb: reference batch) of the reference. If applied to other studies, as well as giving a measure of how potent a mAb is compared to a particular batch of the innovator product (since the same batch was used in every assay), this data could be collated and to highlight any statistically significant differences.
In addition to demonstrating the capability of the J9 cell line to produce a dose response curve with adherent target cells, it was also important to show whether it could accurately reflect reported differences in ADCC activity linked to mAb structural changes including subclass and the N linked glycan. As IgG4 is usually selected when effector functions are not desired, it was unsurprising that the IgG4 form of rituximab did not show an ADCC response with J9 cells, as has been shown using primary cell based assays [7] . Similarly, no response was seen with the IgG2 mAb panitumumab, which only induces ADCC with cells of myeloid lineage via Fc␥RIIa [37] . The N-linked glycans on the Fc region of a mAb in particular are sensitive to conditions used for optimal growth for cells during mAb manufacturing. For example, duration of culture, temperature levels, pH, the presence of cytokines, hormones and other factors in culture media can have a considerable effect on the extent of glycosylation [38] . Despite use of a well-controlled process for manufacturing, glycosylation content may vary between batches of the same mAb. Considering the impact, observed here and widely reported, of a decreased fucose content on ADCC activity, it is important that any variability is detected [39, 40] . Importantly, the implication of the absence of fucose extends to patients who do not respond as effectively to ADCC utilising mAb therapies, potentially due to their possession of the lower affinity F158 CD16 gene polymorphism. Here, non-fucosylated rituximab showed enhanced ADCC compared to the fucosylated mAb when the J9 cell line was used as the effector cell in the assay. This was despite showing comparable target cell binding, and therefore may be due to the observed enhanced CD16 binding as determined by SPR.
Utilisation of the J9 reporter cell line to demonstrate the similar ADCC activity of two rituximab biosimilar products in development suggests that these types of assays are a useful tool for the comparison of biosimilar products, an idea supported by other groups [41] . This is very pertinent to the biosimilar guidance given by the EMA, WHO and FDA for biosimilar product development, which stipulates the need to demonstrate Fc functional activity for mAbs. For demonstrating biosimilarity, more batches of both the reference product, Mabthera and the biosimilar mAbs would need to be examined using a range of methods including orthogonal methods [40] . Our aim was not to establish biosimilarity but to show the utility of the cell-based assay as a tool for determining the ADCC activity of different mAbs. Other techniques used for testing here are also included among the tests required to further demonstrate the similarity of mAbs, relating to the Fc region (CD16 binding, CDC activity and N-glycosylation) and target cell binding.
Despite not having an increased affinity for CD16, ofatumumab had greater ADCC activity than rituximab in the J9 based assay and NK cell based assay. However most groups, using PBMCs as effectors, have reported that both mAbs mediate comparable ADCC activity [40] [41] [42] . While our data diverges from these findings, Craigen et al. [43] demonstrated that, using NK cells from healthy donors, ofatumumab had greater ADCC potency (∼1.8 fold) than rituximab [44] . These data were inclusive of both high and low affinity populations of CD16 on NK cells (10 donors assessed for each) and were statistically significant (p < 0.0001). Furthermore they reported that, using an alternate means of detection than presented here, ofatumumab bound CD16 receptors on NK cells more strongly than rituximab. Overall this shows that purified CD16 expressing effector cells-surrogate or primary NK cell based, may be superior in distinguishing differences between biosimilar products compared with PBMCs. Regarding CDC, using both primary cells and established cell lines as targets, it is evident that ofatumumab is a more potent activator of CDC than rituximab [45, 46] . This was demonstrated here, and is the result of ofatumumab binding to an epitope on CD20 which is closer to the cell surface and retained for a longer duration (i.e. it has a slower off rate). These properties result in more rapid deposition of C3b and, consequently, greater CDC potency compared to rituximab.
To conclude, given both the specificity for ADCC, the versatility with both suspension and adherent cell lines, and an accurate reflection of changes in ADCC activity with mAb structural changes, CD16 expressing reporter gene based ADCC assays provide a viable alternative to traditional ADCC assays. Despite the improved sensitivity of other PBMC or NK based ADCC assays-for example those developed by Gillissen et al. [47] -assay variability remains high, and donors with low affinity CD16 and/or a low proportion of NK cells are unlikely to produce a high ADCC response. The J9 cell line from a bank of low passage cryopreserved cells enables a constant source of reliable surrogate effector cells for assessment of ADCC activity. Given the importance of accounting for cell viability, which can be compromised during the course of the assay, this work shows for the first time the value of incorporating an additional gene, e.g. the renilla luciferase, which is present within the J9 effector cell line. Based on its discriminating potential for different post translational modifications as observed with NK cell based assays, this J9 surrogate cell based ADCC assay can be a useful tool during both the development and assessment of biosimilar and novel mAb products.
